Former Novo Nordisk CEO failed to inform FDA of guideline breach
During his time as CEO of Novo Nordisk, Mads Øvlisen decided not to inform the FDA about breaches of good manufacturing practice at the Danish pharmaceutical company.
When Mads Øvlisen, during his time as CEO at Novo Nordisk, was informed of problems with complying with the US Food and Drug Administration’s (FDA) guidelines on good manufacturing practices, he decided not to inform the US authorities of the violations.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
